James Reeves, MD
Hematology & Oncology · Oklahoma City, OKNPI 1821039892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $722 of the $1,148 with a category attached, or 62.9%. 19 manufacturers reported payments, led by Pfizer at 48.6% of the total. Reporting peaked in 2022 at $455 and has fallen 61.7% since, to $175 in 2024. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 67 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$558
- Novartis$101
- Bristol Myers Squibb$79
- E.r. Squibb & Sons, L.L.C.$57
- AbbVie$49
- Genentech USA, Inc.$47
- plus $258 from 13 others
Across 4 payments — averaging $3103.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$12K
- Merck$500
- TG Therapeutics, Inc.$16
What the payments were for
- Food & beverage$72263%
- Education$42637%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $558 |
| Novartis | 6 | $101 |
| Bristol Myers Squibb | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| AbbVie | 3 | $49 |
| Genentech USA, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $37 |
| Sirtex Medical Inc | 1 | $34 |
| Merck | 2 | $31 |
| Sanofi | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,148 in reported general payments places this provider in the 30th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 44 | $657,747 |
| BrukinsaZanubrutinib | 51 | $480,882 |
| CalquenceAcalabrutinib Maleate | 33 | $455,456 |
| ImbruvicaIbrutinib | 21 | $345,992 |
| VerzenioAbemaciclib | 19 | $285,755 |
| XtandiEnzalutamide | 25 | $242,097 |
| Lenalidomide | 16 | $234,218 |
| KisqaliRibociclib Succinate | 13 | $166,353 |
| PromactaEltrombopag Olamine | 12 | $82,438 |
| EliquisApixaban | 45 | $35,170 |
| Abiraterone Acetate | 15 | $7,561 |
| Exemestane | 30 | $5,812 |
| Anastrozole | 120 | $2,906 |
| Fentanyl | 16 | $1,529 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $15 | $455,45633 claims |
| NovartisKisqali, Promacta | $101 | $248,79125 claims |
| Astellas Pharma US IncXtandi | $37 | $242,09725 claims |
| PfizerEliquis | $558 | $35,17045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.